Overview


According to FutureWise analysis the market for Alzheimer’s Disease Diagnostic is expected to reach US$ 10.86 billion by 2031 at a CAGR of 5.28%.

Alzheimer's is a neurodegenerative disease that starts with minor memory loss and gradually becomes more severe over time. It usually starts with minor memory loss and progresses to the loss of social interaction and communication skills. It is an incurable disease with a long preclinical period and progressive course. It can seriously influence a individual’s ability to carry out daily activities. In most individuals with the disease, those with late-onset symptoms first appear in their mid-60s. Early-onset Alzheimer's is rare and occurs between an individual's 30s and mid-60s. Alzheimer's disease is the most common type of dementia among older adults.

A diagnosis of Alzheimer's disease cannot be determined through a single test, as it requires a comprehensive evaluation to identify specific symptoms and rule out other potential causes of dementia. The process involves a careful medical assessment, which includes obtaining a detailed medical history, conducting mental status testing, performing a thorough physical and neurological examination, and administering blood tests. Brain imaging exams, such as CT scans, PET and MRI, also play a crucial role in the diagnostic process. Computed tomography (CT) head imaging is used to examine the brain for any other potential causes of dementia, such as brain tumors, subdural hematomas, or strokes. On the other hand, MRI uses strong radio frequency pulses, magnetic fields, and a computer to make detailed images of internal body structures, including the brain. MRI can detect brain abnormalities related to mild cognitive impairment (MCI) and may even predict the likelihood of MCI progressing to Alzheimer's.

FutureWise Market Research has published a report that provides an insightful analysis alzheimer’s disease diagnostic market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, alzheimer’s disease diagnostic market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.
 

  • TauRx
  • Alector LLC
  • Eli Lilly and Company
  • Treventis Corporation
  • Neuro-Bio Ltd
  • Accera, Inc.
  • Cognition Therapeutics Inc.
  • Johnson and Johnson
  • F. Hoffmann-La Roche Ltd
  • Quanterix
  • Sysmex
  • Novartis AG
  • Allergan PLC
  • C2N Dignostics
  • Randox Bioscience
  • GE Healthcare
  • MAGQU CO. LTD.
  • Hitachi

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Alzheimer’s Disease Diagnostic Market:

  • In October 2022- Cyclo Therapeutics, Inc. announced the initiation of its Phase 2b study of Trappsol Cyclo for treating Alzheimer's disease by targeting the reduction of amyloid beta and tau. The study received approval from the IRB.
     
  • In September 2022- Esai Co,. Ltd and Biogen Inc. announced favorable topline outcomes from the large-scale global Phase 3 confirmatory Clarity AD clinical trial of lecanemab. Lecanemab is an investigational anti-amyloid beta (A?) protofibril antibody intended for the treatment of MCI due to Alzheimer's disease and mild Alzheimer's disease.

The increasing public and professional awareness of Alzheimer's disease and the advantages of early detection have resulted in higher demand for diagnostic tests. They are expected to drive the market during the forecast period. Patients are becoming proactive about their health, seeking early diagnosis for potential cognitive issues. Healthcare professionals are also more attentive in identifying early symptoms, leading to a surge in diagnostic screenings. The emphasis on early detection is driven by the understanding that early intervention allows for better disease management, allowing patients to access appropriate care and treatment plans at the earliest stage. Moreover, the growing aging population is the major driver for the Alzheimer's Disease Diagnostic market. With the rise in life expectancy and an increasing aging population, the prevalence of Alzheimer's disease and related cognitive disorders also increases. This demographic shift has led to a greater need for accurate and accessible diagnostic tests to identify and manage these conditions in their early stages. Therefore, healthcare providers and government bodies are encouraged to invest in innovative diagnostic technologies to cater to the increasing demand for early detection and treatment among the elderly population. Furthermore, high development costs are expected to obstruct the Alzheimer’s Disease Diagnostic market. The substantial investments required for research, clinical trials, and regulatory approvals may impede the widespread availability and adoption of new diagnostic tools, particularly in developing regions with limited resources and healthcare infrastructure. The financial burden may deter smaller companies or research organizations from entering the market, potentially slowing innovation and limiting the accessibility of advanced diagnostic solutions in certain areas.
 

By Product Type

  • Brain Imaging
  • CFS Test for Alzheimer's Disease

By Type

  • Early-Onset
  • Late-Onset
  • Familial

By End-Use

  • Hospitals
  • Specialty Clinics/ Diagnostic Centers
  • Ambulatory Surgical Centers
  • Academic and Research Institutes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Growing incidences of Alzheimer's disease with an increase in the geriatric population, huge investment in research and development activities, the launch of new products, and expansion of technological developments in the region. For instance, As of March 2022, the Alzheimer's Association Report indicated that around 6.2 million individuals aged 65 years and more were living with Alzheimer's-related dementia in the United States. Estimations suggest that this number will escalate to 13.8 million individuals by 2060. Furthermore, high healthcare expenses and funds by the key players, in turn, are expected to boost the growth of the Alzheimer's disease diagnostic market in the region. The factors mentioned above are expected to drive the market during the forecast period.
 

 


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Alzheimer’s Disease Diagnostic Market By Product Type, By Type, By End-Use and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.  Alzheimer’s Disease Diagnostic Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Alzheimer’s Disease Diagnostic Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Alzheimer’s Disease Diagnostic Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Alzheimer’s Disease Diagnostic Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Brain Imaging
        2. CFS Test for Alzheimer's Disease

  • 8.  Alzheimer’s Disease Diagnostic Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Early-Onset
        2. Late-Onset
        3. Familial

  • 9.   Alzheimer’s Disease Diagnostic Market, By End-Use Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics/ Diagnostic Centers
        3. Ambulatory Surgical Centers
        4. Academic and Research Institutes

  • 10.   North America Alzheimer’s Disease Diagnostic Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Alzheimer’s Disease Diagnostic Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Alzheimer’s Disease Diagnostic Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2023-2031
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Alzheimer’s Disease Diagnostic Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. TauRx
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Alector LLC
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Eli Lilly and Company
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Treventis Corporation
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Neuro-Bio Ltd
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Accera, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Cognition Therapeutics Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Johnson and Johnson
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. F. Hoffmann-La Roche Ltd
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Quanterix
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Sysmex
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Novartis AG
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Allergan PLC
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. C2N Dignostics
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Randox Bioscience
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. GE Healthcare
         1. Company Overview
         2. Product Portfolio
         3. SWOT Analysis
         4. Financial Overview
         5. Strategic Overview
        17. MAGQU CO. LTD.
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Hitachi
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients